利用抗肿瘤药靶—酪氨酸激酶从广西特色中草药中筛选和研究选择性抗肿瘤药
|
摘要
目的：
利用抗肿瘤药靶-酪氨酸激酶从18种广西常用中草药(瑶药、壮药)中筛选和研究选择性抗肿瘤药物
方法：
醇提取十八种广西特色中草药(其中瑶药8种,壮药10种),采用MTT法测定其体外对人肝癌SMMC-7721细胞的抑制作用；选取体外抑瘤作用较好的药物,根据血清药理学方法制备含药血清,观察其体外对人肝癌细胞SMMC-7721的抑制作用；通过细胞裂解液提取不同作用时间不同作用剂量下的人肝癌细胞SMMC-7721总蛋白,采用ELISA法测定人肝癌细胞SMMC-7721总蛋白中酪氨酸激酶(TPK)含量,观察不同药物提取物对其含量影响；通过建立鸡胚绒毛尿囊膜模型测定不同药物提取物抗血管生成的抑制作用；建立人肝癌细胞SMMC-7721裸鼠移植瘤模型,观察不同药物治疗组对裸鼠移植瘤的影响,HE染色观察肿瘤生长及其血管生长情况,免疫组化法检测瘤组织中VEGF.CD34的表达。
结果：
在筛选的特色药物中,瑶药2号、瑶药5号体外抑制人肝癌SMMC-7721的作用较强,IC50分别为O.080mg/ml,0.281mg/ml;血清药理学实验结果显示瑶药2号、瑶药5号、索拉菲尼的含药血清均显示出不同程度的体外抗肿瘤作用,其中10%瑶药2号含药血清组抑瘤作用与10%索拉菲尼含药血清组相比,抑制率为11.15%,抑制作用变强(P<0.05)；瑶药2号、瑶药5号可不同程度的降低酪氨酸激酶的含量(P<0.01)：12.5mg/L索拉菲尼、50mg/mL瑶药2号、12.5mg/mL～50mg/mL瑶药5号均有不同程度的抑制鸡胚尿囊血管生长作用,与空白对照组相比,索拉菲尼对各级血管均有明显抑制作用(P<0.01),瑶药2号高剂量组对二、三级血管有抑制作用(P<0.01),瑶药5号对三级血管有抑制作用,高剂量时可同时抑制一、二级血管(P<0.01)；索拉菲尼组,瑶药2号高剂量组、瑶药2号中剂量组肿瘤瘤重、相对体积明显低于阴性对照组(P<0.01),其抑瘤率分别为51.75%,47.71%,21.27%；HE染色显示索拉菲尼组、瑶药2号高剂量组肿瘤坏死区域明显大于阴性对照组；索拉菲尼组、瑶药2号高剂量组MVD明显低于阴性对照组(P<0.01),瑶药2号中剂量组与阴性对照组相比也有差异(P<0.05)；索拉菲尼组、瑶药2号高剂量组可明显降低肿瘤组织内VEGF的表达(P<0.01)。
结论：
瑶药2号、瑶药5号均可不同程度的抑制血管生长,可降低肿瘤细胞内酪氨酸激酶的含量。此外,瑶药2号还可降低肿瘤内微血管密度以及VEGF的表达。
Objective:
To screen and research targeting anti-hepatoma drugs from18kinds of the traditional Chinese herbal medicines from Yao medicin,Chuang medicine in Guangxi by antitumor drug target as tyrosine kinase.
Methods:
18Ethanol extracts of Yao medicines,Chuang medicines in Guangxi were obtained by cold-extraction alcohol,then the inhibitory activity of human hepatoma cell line SMMC-7721with MTT were determined in vitro.The medicated serums with obviously anti-tumor effect of enthanol extracts were prepared according to the serum pharmacology method and further observed its inhibiting effect in same tumor cell line by MTT.The total protein of human hepatoma cell line SMMC-7721at different time or concentration of extracts was extracted by cell lysis buffer,respectively.The content of tyrosine kinase in total protein of tumor cells was detected by Enzyme-linked immunosorbent assay (ELISA). The model of angiogenesis in allantocheriionof chick embroyo was established so as to observe antiangiogenesis effect of extracts by CAM assay in vivo.The models of xenografted tumor in nude mice with human hepatoma cell line SMMC-7721were established,and then observated the tumor growth by HE staining and expression of VEGF,CD34in tumor tissues of each group by immunohistochemistry method.
Results:
Yao medicine2and Yao medicine5had stronger anti-tumor ability to human hepatoma cell line SMMC-7721among the screening drugs,the IC50was0.080mg/ml,0.281mg/ml,respectively.Experimental results of serum pharmacology showed medicated serum inhibited the growth of human hepatoma cell line SMMC-7721in varying degrees.10%serum of Yao medicine2group had an obvious inhibition effect on tumor compared with10%serum of sorafenib group, the inhibitory rate was11.15%.There was significant differences between two groups (P<0.05).Yao medicine2and Yao medicine5reduced the level of tyrosine kinase (p<0.01).12.5mg/L sorafenib,50mg/mL Yao medicine2and12.5mg/mL-50mg/mL Yao medicine5inhibited the angiogenesis of CAM in varying degrees.Compared with control group,sorafenib had a significant inhibition on different levels of blood vessels(p<0.01).High dose of Yao medicine2had inhibition on two or three-level blood vessels (p<0.01).Yao medicine5had inhibition on three-level blood vessels,while inhibiting one or two-level blood vessels under high dosage (p<0.01).The tumor weight and tumor relative volume in the following groups,such as sorafenib group,high-dose Yao medicine2group and medium-dose Yao medicine2group,was significantly lower than control group(P<0.01). The result of HE staining showed that tumor necrotic area in sorafenib group and high-dosage Yao medicine2group was significantly greater than control group.MVD were lower of sorafenib group and high-dosage Yao medicine2group than that of control group (P<0.01).There were significant differences between medium-dose Yao medicine2group and control group (P<0.05). Sorafenib group and high-dose Yao medicine2group reduced significantly the expression of VEGF in tumor tissues (P<0.01).
Conclusion:
Yao medicine2and Yao medicine5not only can inhibit the growth of blood vessels in varying degrees,but also can reduces the content of tyrosine kinases in tumor cells.In addition,MVD and the expression of VEGF may be reduced because of Yao medicine2.
利用抗肿瘤药靶-酪氨酸激酶从18种广西常用中草药(瑶药、壮药)中筛选和研究选择性抗肿瘤药物
方法：
醇提取十八种广西特色中草药(其中瑶药8种,壮药10种),采用MTT法测定其体外对人肝癌SMMC-7721细胞的抑制作用；选取体外抑瘤作用较好的药物,根据血清药理学方法制备含药血清,观察其体外对人肝癌细胞SMMC-7721的抑制作用；通过细胞裂解液提取不同作用时间不同作用剂量下的人肝癌细胞SMMC-7721总蛋白,采用ELISA法测定人肝癌细胞SMMC-7721总蛋白中酪氨酸激酶(TPK)含量,观察不同药物提取物对其含量影响；通过建立鸡胚绒毛尿囊膜模型测定不同药物提取物抗血管生成的抑制作用；建立人肝癌细胞SMMC-7721裸鼠移植瘤模型,观察不同药物治疗组对裸鼠移植瘤的影响,HE染色观察肿瘤生长及其血管生长情况,免疫组化法检测瘤组织中VEGF.CD34的表达。
结果：
在筛选的特色药物中,瑶药2号、瑶药5号体外抑制人肝癌SMMC-7721的作用较强,IC50分别为O.080mg/ml,0.281mg/ml;血清药理学实验结果显示瑶药2号、瑶药5号、索拉菲尼的含药血清均显示出不同程度的体外抗肿瘤作用,其中10%瑶药2号含药血清组抑瘤作用与10%索拉菲尼含药血清组相比,抑制率为11.15%,抑制作用变强(P<0.05)；瑶药2号、瑶药5号可不同程度的降低酪氨酸激酶的含量(P<0.01)：12.5mg/L索拉菲尼、50mg/mL瑶药2号、12.5mg/mL～50mg/mL瑶药5号均有不同程度的抑制鸡胚尿囊血管生长作用,与空白对照组相比,索拉菲尼对各级血管均有明显抑制作用(P<0.01),瑶药2号高剂量组对二、三级血管有抑制作用(P<0.01),瑶药5号对三级血管有抑制作用,高剂量时可同时抑制一、二级血管(P<0.01)；索拉菲尼组,瑶药2号高剂量组、瑶药2号中剂量组肿瘤瘤重、相对体积明显低于阴性对照组(P<0.01),其抑瘤率分别为51.75%,47.71%,21.27%；HE染色显示索拉菲尼组、瑶药2号高剂量组肿瘤坏死区域明显大于阴性对照组；索拉菲尼组、瑶药2号高剂量组MVD明显低于阴性对照组(P<0.01),瑶药2号中剂量组与阴性对照组相比也有差异(P<0.05)；索拉菲尼组、瑶药2号高剂量组可明显降低肿瘤组织内VEGF的表达(P<0.01)。
结论：
瑶药2号、瑶药5号均可不同程度的抑制血管生长,可降低肿瘤细胞内酪氨酸激酶的含量。此外,瑶药2号还可降低肿瘤内微血管密度以及VEGF的表达。
Objective:
To screen and research targeting anti-hepatoma drugs from18kinds of the traditional Chinese herbal medicines from Yao medicin,Chuang medicine in Guangxi by antitumor drug target as tyrosine kinase.
Methods:
18Ethanol extracts of Yao medicines,Chuang medicines in Guangxi were obtained by cold-extraction alcohol,then the inhibitory activity of human hepatoma cell line SMMC-7721with MTT were determined in vitro.The medicated serums with obviously anti-tumor effect of enthanol extracts were prepared according to the serum pharmacology method and further observed its inhibiting effect in same tumor cell line by MTT.The total protein of human hepatoma cell line SMMC-7721at different time or concentration of extracts was extracted by cell lysis buffer,respectively.The content of tyrosine kinase in total protein of tumor cells was detected by Enzyme-linked immunosorbent assay (ELISA). The model of angiogenesis in allantocheriionof chick embroyo was established so as to observe antiangiogenesis effect of extracts by CAM assay in vivo.The models of xenografted tumor in nude mice with human hepatoma cell line SMMC-7721were established,and then observated the tumor growth by HE staining and expression of VEGF,CD34in tumor tissues of each group by immunohistochemistry method.
Results:
Yao medicine2and Yao medicine5had stronger anti-tumor ability to human hepatoma cell line SMMC-7721among the screening drugs,the IC50was0.080mg/ml,0.281mg/ml,respectively.Experimental results of serum pharmacology showed medicated serum inhibited the growth of human hepatoma cell line SMMC-7721in varying degrees.10%serum of Yao medicine2group had an obvious inhibition effect on tumor compared with10%serum of sorafenib group, the inhibitory rate was11.15%.There was significant differences between two groups (P<0.05).Yao medicine2and Yao medicine5reduced the level of tyrosine kinase (p<0.01).12.5mg/L sorafenib,50mg/mL Yao medicine2and12.5mg/mL-50mg/mL Yao medicine5inhibited the angiogenesis of CAM in varying degrees.Compared with control group,sorafenib had a significant inhibition on different levels of blood vessels(p<0.01).High dose of Yao medicine2had inhibition on two or three-level blood vessels (p<0.01).Yao medicine5had inhibition on three-level blood vessels,while inhibiting one or two-level blood vessels under high dosage (p<0.01).The tumor weight and tumor relative volume in the following groups,such as sorafenib group,high-dose Yao medicine2group and medium-dose Yao medicine2group,was significantly lower than control group(P<0.01). The result of HE staining showed that tumor necrotic area in sorafenib group and high-dosage Yao medicine2group was significantly greater than control group.MVD were lower of sorafenib group and high-dosage Yao medicine2group than that of control group (P<0.01).There were significant differences between medium-dose Yao medicine2group and control group (P<0.05). Sorafenib group and high-dose Yao medicine2group reduced significantly the expression of VEGF in tumor tissues (P<0.01).
Conclusion:
Yao medicine2and Yao medicine5not only can inhibit the growth of blood vessels in varying degrees,but also can reduces the content of tyrosine kinases in tumor cells.In addition,MVD and the expression of VEGF may be reduced because of Yao medicine2.
引文
[1]Mendelohn J.Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy[J].Clin Cancer Res,1997,3(12):2703-2707.
[2]Gordana Vlahovic,Jeffrey Crford.Actieation of tyrosine kinase in cancer.The Oncologist,2003,8:531-538.
[3]Waltenberger J,Welsh LC,Siegbhn A,etal.Different signal transduction prop-erties of KDR and fit-1,two receptors for vascular endothelial growth factor [J].The J Biol Chem,1994,269:26988-26995.
[4]Ferrer FA,M iller LJ,Richard Lindoquist,etal.Expression of vascular endo-thelial growth factor receptors in human prostate cancer [J].Juroe,1999,54: 567-572.
[5]Kawaii S,Tomon Y,Kataes E,etal.Antiproliferative activity on several cell celllines.Biosci Biotechnol Biochem,1999,63(5):896-899.
[6]Josefa Y,Vicents V,Miguel A,etal.Cytotoxicity and antiproliferative activities of several phenolic compounds against three melanocytes cell lines relationship between structure and activity.Nutr Cancer,2004,49(2):191-199.
[7]John A,Manthey Y,Najla GAntiproliferative activities of citrus flavonoids against six human cancer cell lines.JAg-ric FoodChem,2002,50:5837-5843.
[8]韦金育,李延,韦涛等,50种广西常用中草药、壮药抗肿瘤作用的筛选研究.广西中医学院学报,2003.6(4)：3-7.
[9]庞声航,余胜民,黄琳芸等,广西20种传统瑶药抗肿瘤筛选研究.广西中医药,2006.29(4)：53-57
[10]伍婧,罗荣城,张华等,索拉菲尼联合三氧化二砷对肝癌细胞株的抑制作用.南方医科大学学报,2008.28(4)：639-641,645.
[11]何前松,孟庆华,冯泳,阳和汤含药血清体外对肝癌细胞SMMC-7721生长增殖的影响.贵阳中医学院学报,2011.33(3)：118-122.
[12]李大勇,陈文娜,刘艳玲等,疏肝活血方含药血清对鸡胚绒毛尿囊膜血管生成的影响.中国中医基础杂志,2009.15(8)：623-624.
[13]梁宁,庞宇舟,赖德禄,依肝癌含药血清体外抗肿瘤作用.中国实验方剂学杂志,2011.17(12)：196-197.
[14]赵斌,葛金芳,朱娟娟等,小议在MTT法检测细胞增殖抑制率中IC50的计算方法.安徽医药,2007.11(9)：834-835.
[15]农朝赞,黄华艺,黄酮类化合物对蛋白激酶的抑制作用.中国新药与临床杂志,2004,23(8)：548-551.
[16]Langner C,von Wasielewski R,Ratschek M,etal.Biological significance of p27 and Skp2 expressionin renal cell carcinoma [J].Virchows Arch,2004, 445(6):631-636.
[17]Liu L,Cao Y,Chen C.etal.Sorafenib blocks the RAF/MEK/EPK pathway, inhibits tumor angiongeneis,and induces tumor cell apoptosis in hepato-cellular caricinoma model PLC/PRF/5[J].CancerRes,2006,66(24):11851-11858
[18]孟李,王宁生,含药血清的制备研究.中药新药与临床药理1999.10(5)：290-292.
[1]Zetter BR.Angiogenesis and tumor metastasis.Annu Rev Med,1998,49:407
[2]崔瑶,罗荣城,李爱民,索拉菲尼联合肝素抑制血管生成的研究.解放军医学杂志,2008.33(5)：555-557.
[3]邓秀梅,余伟,陈丽等,蜈蚣多糖蛋白复合物对鸡胚绒毛尿囊膜血管生成的影响.数理医药学杂志,2011.24(2)：173-174.
[4]刘北忠,蒋纪恺,何於娟等,苦参碱对K562细胞蛋白酪氨酸激酶及磷酸酶活性的影响.癌症.2002.21(12)：1292-1295.
[5]许娇红,张志强,刘洋等,姜黄素衍生物对K562细胞酪氨酸激酶活性的影响.福建医科大学学报,2010.44(3)：165-167.
[6]Li JM, Han JS,Huang Y,etal.A novelgene delivery system targeting cells expressing VEGF receptors [J]. CellRes,1999,9(1):11-25.
[7]Niederman TM,Ghogawala Z,Carter BS,etal. Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors [J].Proc Natl Acad Sci USA,2002,99(10):7009
[8]李大勇,陈文娜,刘艳玲等,疏肝活血方含药血清对鸡胚绒毛尿囊膜血管生成的影响.中国中医基础杂志,2009.15(8)：623-624.
[9]许扬,潘瑞乐,常琪等,龙葵抑制鸡胚绒毛尿囊膜血管新生的研究.中国中药杂志,2008.33(5)：549-552
[1]中华抗癌协会肝癌专业委员会.原发性肝癌的临床诊断与分期标准(2001年广州第八届肝癌学会会议)[J],现代实用医学,2002,15(4)：21
[2]Holash J,Wiegand SJ,Yancopoulos GD.New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiop-oietins and VEGF.Oncogene 1999,18:5356-5362
[3]陈逢生,崔彦芝,郑航等,索拉菲尼联合顺铂对人肝癌裸鼠移植瘤生长的抑制作用.山东医药,2009.49(48)：9-11.
[4]贺凯,刘明华,任美萍等,槲皮素对裸鼠人肝癌细胞株SMMC-7721移植瘤生长的抑制作用.实用肿瘤杂志,2011.26(5)：493-495.
[5]何志军,陈先祥,蔡庆和等,p27mt对裸鼠肝癌移植瘤组织VEGF表达的影响.湖北医药学院学报,2011.30(1)：26-28.
[6]王彦敏,血管生成因子VEGF研究进展.河北医药,2010.32(11)：1456-1458.
[7]Fukumura D,Xavier R,Sugiura T,etal.Tumor induction of VEGF promoter activity in stromal ceils[J].Cell,1998,94(6):715-725.
[8]黎莉.表没食子儿茶素没食子酸酯逆转人口腔鳞癌多药耐药性与其血管生长作用关系的实验研究[D].广西医科大学,2004.
[9]Langner C,von Wasielewski R,Ratschek M,etal.Biological significance of p27 and Skp2 expressionin renal cell carcinoma [J].Virchows Arch,2004, 445(6):631-636.
[10]Liu L,Cao Y,Chen C,etal.Sorafenib blocks the RAF/MEK/EPK path-way,inhibits tumor angiongeneis,and induces tumor cell apoptosis in hepatocellular caricinoma model PLC/PRF/5[J].CancerRes,2006,66(24): 11851-11858
[11]郑培实,张阳,蒋葵等,索拉菲尼联合华蟾素对离体肝癌细胞株SMMC-7721的协同抑制效应观察.山东医药,2011.51(19)：69-70.
[12]Ellis L M,Takahashi Y,Fenoglio CJ,etal.Vessel counts and vascular endo-thelial growth factor expression in pancreaticedenocarcinoma [J]. Eur.J. Cancer,1998,34:337
[13]Bockhorn M, Tsuzuki Y, Xu L, etal.Differential vascular and transcrip-tional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts[J].Clin Cancer Res,2003, 9(11):4221-4226.
[1]Gordana Vlahovic,Jeffrey Crford.Actieation of tyrosine kinase in cancer.The Oncologist,2003,8:531-538.
[2]Slichenmyer WJ,Fry DW.Anticancer therapy targeting the erbB family of receptor tyrosine kinases.Semin Oncol,2001,28:67-79.
[3]甄永苏,邵荣光,李电东等.抗肿瘤药物研究与开发.第一版.北京：化学工业出版社,2004,592-593.
[4]郑素军,林汝仙,王升启.血管内皮生长因子受体-2及其信号转导作用的研究进展.国外医学药学分册,2005,32：161-180.
[5]庄洪军,张全安,赵伟.血管内皮生长因子及其受体与肝癌治疗的研究进展.肿瘤研究与Ⅰ临床,2008,6：1618-1621.
[6]何立丽,苏航,张伟京等.血管内皮细胞生长因子与抗肿瘤转移治疗的研究.国外医学药学分册,2006,33：2118-2121.
[7]何振辉,梁念慈.以VEGF和bFGF及其受体为靶点的抗肿瘤血管治疗.国外医学生理病理科学与临床分册,2004,24：162-166.
[8]BLUME-JENSEN P, HUNTER T. Oncogenic kinase signalling[J].Nature, 2001,411(6835):355-365.
[9]Oilawa T,Ashino H,Shimamura M,etal.Inhibition of angiogenesis by erbstatin,an inhibitor of tyrosine kinase [J].J Antibiot,1993,46(5):785-790.
[10]Buchanan M S, Carroll A R, Edser A,etal.Tyrosine kinase inhibitors from the rainforest tree Polyscias murrayi[J].Phytochemistry,2005,66(4):48-485.
[11]Graziani Y etal.Eur J Biochem,1983,135:583-589.
[12]Geahlen R L, Koonchanok N M, Mclaughlin J L,etal.Inhibition of protein-tyrosine kinase activity by flavanoids and related compounds [J].J Nat Prod, 1989,52(5):982-986.
[13]Akiyama T etal.J Bio Chem,1987,262(12):5592-5595.
[14]Onoda T,Iinuma H, Sasaki Y,etal.Isolation of a noveltyrosine kinase inhi-bitor, lavendustin A, from Streptomyces griseolavendus[J].J Nat Prod,1989, 52(6):1252-1257.
[15]Onada T etal.J Nat Prod.l989,52:1352-1357.
[16]Lee R H, Slate D L, Alvi K A,etal,Marine spongpolyketide inhibitors of protein tyrosine kinase [J]·Biochem Biophys Res Commun,1992,184(2): 765-772.
[17]Duros J etal. In Cancer Treatment Review,Vol8. p63～87 Academic Press, New York,1981.
[18]Uehara Y etal,Virology,1988,164:294-298.
[19]Fu X, Schmitz F J, Lee R H,etal.Inhibitors of proteintyrosine kinase pp60vv-src:sterol sulfates from the brittle star Ophiarachna incrassata[J].J Nat Prod,1994,57(11):1591-1594.
[20]Govindan M, Schmitz Z F J,Lee R H,etal.New cycloartanol sulfates from the alga Tydemaniaexpenitionis:Inhibitors of the protein tyrosine kinase pp60v-src[J].J Nat Prod,1994,57(1):74-78.
[21]Marcu M,Chadli A,Catelli M,etal.The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone [J].J Biol Chem,2000,275(47): 37181-37186.
[22]Vazquez M J,Vega A,Diez E,etal.Novel sesquiterpenoid as tyrosine kinase inhibitors produced by Stachy botry chortarum [J].Tetrahedron,2004,60(10): 2379-2385.
[2]Gordana Vlahovic,Jeffrey Crford.Actieation of tyrosine kinase in cancer.The Oncologist,2003,8:531-538.
[3]Waltenberger J,Welsh LC,Siegbhn A,etal.Different signal transduction prop-erties of KDR and fit-1,two receptors for vascular endothelial growth factor [J].The J Biol Chem,1994,269:26988-26995.
[4]Ferrer FA,M iller LJ,Richard Lindoquist,etal.Expression of vascular endo-thelial growth factor receptors in human prostate cancer [J].Juroe,1999,54: 567-572.
[5]Kawaii S,Tomon Y,Kataes E,etal.Antiproliferative activity on several cell celllines.Biosci Biotechnol Biochem,1999,63(5):896-899.
[6]Josefa Y,Vicents V,Miguel A,etal.Cytotoxicity and antiproliferative activities of several phenolic compounds against three melanocytes cell lines relationship between structure and activity.Nutr Cancer,2004,49(2):191-199.
[7]John A,Manthey Y,Najla GAntiproliferative activities of citrus flavonoids against six human cancer cell lines.JAg-ric FoodChem,2002,50:5837-5843.
[8]韦金育,李延,韦涛等,50种广西常用中草药、壮药抗肿瘤作用的筛选研究.广西中医学院学报,2003.6(4)：3-7.
[9]庞声航,余胜民,黄琳芸等,广西20种传统瑶药抗肿瘤筛选研究.广西中医药,2006.29(4)：53-57
[10]伍婧,罗荣城,张华等,索拉菲尼联合三氧化二砷对肝癌细胞株的抑制作用.南方医科大学学报,2008.28(4)：639-641,645.
[11]何前松,孟庆华,冯泳,阳和汤含药血清体外对肝癌细胞SMMC-7721生长增殖的影响.贵阳中医学院学报,2011.33(3)：118-122.
[12]李大勇,陈文娜,刘艳玲等,疏肝活血方含药血清对鸡胚绒毛尿囊膜血管生成的影响.中国中医基础杂志,2009.15(8)：623-624.
[13]梁宁,庞宇舟,赖德禄,依肝癌含药血清体外抗肿瘤作用.中国实验方剂学杂志,2011.17(12)：196-197.
[14]赵斌,葛金芳,朱娟娟等,小议在MTT法检测细胞增殖抑制率中IC50的计算方法.安徽医药,2007.11(9)：834-835.
[15]农朝赞,黄华艺,黄酮类化合物对蛋白激酶的抑制作用.中国新药与临床杂志,2004,23(8)：548-551.
[16]Langner C,von Wasielewski R,Ratschek M,etal.Biological significance of p27 and Skp2 expressionin renal cell carcinoma [J].Virchows Arch,2004, 445(6):631-636.
[17]Liu L,Cao Y,Chen C.etal.Sorafenib blocks the RAF/MEK/EPK pathway, inhibits tumor angiongeneis,and induces tumor cell apoptosis in hepato-cellular caricinoma model PLC/PRF/5[J].CancerRes,2006,66(24):11851-11858
[18]孟李,王宁生,含药血清的制备研究.中药新药与临床药理1999.10(5)：290-292.
[1]Zetter BR.Angiogenesis and tumor metastasis.Annu Rev Med,1998,49:407
[2]崔瑶,罗荣城,李爱民,索拉菲尼联合肝素抑制血管生成的研究.解放军医学杂志,2008.33(5)：555-557.
[3]邓秀梅,余伟,陈丽等,蜈蚣多糖蛋白复合物对鸡胚绒毛尿囊膜血管生成的影响.数理医药学杂志,2011.24(2)：173-174.
[4]刘北忠,蒋纪恺,何於娟等,苦参碱对K562细胞蛋白酪氨酸激酶及磷酸酶活性的影响.癌症.2002.21(12)：1292-1295.
[5]许娇红,张志强,刘洋等,姜黄素衍生物对K562细胞酪氨酸激酶活性的影响.福建医科大学学报,2010.44(3)：165-167.
[6]Li JM, Han JS,Huang Y,etal.A novelgene delivery system targeting cells expressing VEGF receptors [J]. CellRes,1999,9(1):11-25.
[7]Niederman TM,Ghogawala Z,Carter BS,etal. Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors [J].Proc Natl Acad Sci USA,2002,99(10):7009
[8]李大勇,陈文娜,刘艳玲等,疏肝活血方含药血清对鸡胚绒毛尿囊膜血管生成的影响.中国中医基础杂志,2009.15(8)：623-624.
[9]许扬,潘瑞乐,常琪等,龙葵抑制鸡胚绒毛尿囊膜血管新生的研究.中国中药杂志,2008.33(5)：549-552
[1]中华抗癌协会肝癌专业委员会.原发性肝癌的临床诊断与分期标准(2001年广州第八届肝癌学会会议)[J],现代实用医学,2002,15(4)：21
[2]Holash J,Wiegand SJ,Yancopoulos GD.New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiop-oietins and VEGF.Oncogene 1999,18:5356-5362
[3]陈逢生,崔彦芝,郑航等,索拉菲尼联合顺铂对人肝癌裸鼠移植瘤生长的抑制作用.山东医药,2009.49(48)：9-11.
[4]贺凯,刘明华,任美萍等,槲皮素对裸鼠人肝癌细胞株SMMC-7721移植瘤生长的抑制作用.实用肿瘤杂志,2011.26(5)：493-495.
[5]何志军,陈先祥,蔡庆和等,p27mt对裸鼠肝癌移植瘤组织VEGF表达的影响.湖北医药学院学报,2011.30(1)：26-28.
[6]王彦敏,血管生成因子VEGF研究进展.河北医药,2010.32(11)：1456-1458.
[7]Fukumura D,Xavier R,Sugiura T,etal.Tumor induction of VEGF promoter activity in stromal ceils[J].Cell,1998,94(6):715-725.
[8]黎莉.表没食子儿茶素没食子酸酯逆转人口腔鳞癌多药耐药性与其血管生长作用关系的实验研究[D].广西医科大学,2004.
[9]Langner C,von Wasielewski R,Ratschek M,etal.Biological significance of p27 and Skp2 expressionin renal cell carcinoma [J].Virchows Arch,2004, 445(6):631-636.
[10]Liu L,Cao Y,Chen C,etal.Sorafenib blocks the RAF/MEK/EPK path-way,inhibits tumor angiongeneis,and induces tumor cell apoptosis in hepatocellular caricinoma model PLC/PRF/5[J].CancerRes,2006,66(24): 11851-11858
[11]郑培实,张阳,蒋葵等,索拉菲尼联合华蟾素对离体肝癌细胞株SMMC-7721的协同抑制效应观察.山东医药,2011.51(19)：69-70.
[12]Ellis L M,Takahashi Y,Fenoglio CJ,etal.Vessel counts and vascular endo-thelial growth factor expression in pancreaticedenocarcinoma [J]. Eur.J. Cancer,1998,34:337
[13]Bockhorn M, Tsuzuki Y, Xu L, etal.Differential vascular and transcrip-tional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts[J].Clin Cancer Res,2003, 9(11):4221-4226.
[1]Gordana Vlahovic,Jeffrey Crford.Actieation of tyrosine kinase in cancer.The Oncologist,2003,8:531-538.
[2]Slichenmyer WJ,Fry DW.Anticancer therapy targeting the erbB family of receptor tyrosine kinases.Semin Oncol,2001,28:67-79.
[3]甄永苏,邵荣光,李电东等.抗肿瘤药物研究与开发.第一版.北京：化学工业出版社,2004,592-593.
[4]郑素军,林汝仙,王升启.血管内皮生长因子受体-2及其信号转导作用的研究进展.国外医学药学分册,2005,32：161-180.
[5]庄洪军,张全安,赵伟.血管内皮生长因子及其受体与肝癌治疗的研究进展.肿瘤研究与Ⅰ临床,2008,6：1618-1621.
[6]何立丽,苏航,张伟京等.血管内皮细胞生长因子与抗肿瘤转移治疗的研究.国外医学药学分册,2006,33：2118-2121.
[7]何振辉,梁念慈.以VEGF和bFGF及其受体为靶点的抗肿瘤血管治疗.国外医学生理病理科学与临床分册,2004,24：162-166.
[8]BLUME-JENSEN P, HUNTER T. Oncogenic kinase signalling[J].Nature, 2001,411(6835):355-365.
[9]Oilawa T,Ashino H,Shimamura M,etal.Inhibition of angiogenesis by erbstatin,an inhibitor of tyrosine kinase [J].J Antibiot,1993,46(5):785-790.
[10]Buchanan M S, Carroll A R, Edser A,etal.Tyrosine kinase inhibitors from the rainforest tree Polyscias murrayi[J].Phytochemistry,2005,66(4):48-485.
[11]Graziani Y etal.Eur J Biochem,1983,135:583-589.
[12]Geahlen R L, Koonchanok N M, Mclaughlin J L,etal.Inhibition of protein-tyrosine kinase activity by flavanoids and related compounds [J].J Nat Prod, 1989,52(5):982-986.
[13]Akiyama T etal.J Bio Chem,1987,262(12):5592-5595.
[14]Onoda T,Iinuma H, Sasaki Y,etal.Isolation of a noveltyrosine kinase inhi-bitor, lavendustin A, from Streptomyces griseolavendus[J].J Nat Prod,1989, 52(6):1252-1257.
[15]Onada T etal.J Nat Prod.l989,52:1352-1357.
[16]Lee R H, Slate D L, Alvi K A,etal,Marine spongpolyketide inhibitors of protein tyrosine kinase [J]·Biochem Biophys Res Commun,1992,184(2): 765-772.
[17]Duros J etal. In Cancer Treatment Review,Vol8. p63～87 Academic Press, New York,1981.
[18]Uehara Y etal,Virology,1988,164:294-298.
[19]Fu X, Schmitz F J, Lee R H,etal.Inhibitors of proteintyrosine kinase pp60vv-src:sterol sulfates from the brittle star Ophiarachna incrassata[J].J Nat Prod,1994,57(11):1591-1594.
[20]Govindan M, Schmitz Z F J,Lee R H,etal.New cycloartanol sulfates from the alga Tydemaniaexpenitionis:Inhibitors of the protein tyrosine kinase pp60v-src[J].J Nat Prod,1994,57(1):74-78.
[21]Marcu M,Chadli A,Catelli M,etal.The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone [J].J Biol Chem,2000,275(47): 37181-37186.
[22]Vazquez M J,Vega A,Diez E,etal.Novel sesquiterpenoid as tyrosine kinase inhibitors produced by Stachy botry chortarum [J].Tetrahedron,2004,60(10): 2379-2385.